Kymera Therapeutics Inc (NAS:KYMR)
$ 47.74 0.89 (1.9%) Market Cap: 3.09 Bil Enterprise Value: 2.57 Bil PE Ratio: 0 PB Ratio: 3.46 GF Score: 50/100

Kymera Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 02:00PM GMT
Release Date Price: $53.83 (-1.39%)
Eric Joseph
PhD,

Welcome again to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst with the firm. And our next presenting company is Kymera Therapeutics. It's my pleasure to welcome the company's CEO, Nello Mainolfi, to talk to us a little bit about the company. There is a Q&A session after the presentation. Feel free to submit questions by clicking the icon over there, and I'll work them in where appropriate. So with that, Nello, thanks for showing some of your time with us this morning.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Eric. Thanks for the invitation to participate in the conference. I'm excited to share with everybody our story today. So first of all, maybe just to remind everybody, Kymera has been evolving quite rapidly in the past 2, 3 years. I would say, thanks to an amazing team of dedicated, I call it, R&D entrepreneurs, but also thanks to supporting both partners and investors. So today, I do want to talk about our pipeline progression and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot